Institutional members access full text with Ovid®

NKG2C is a major triggering receptor involved in the V1 T cell-mediated cytotoxicity against HIV-infected CD4 T cells

Fausther-Bovendo, Huguesa; Wauquier, Nadiaa; Cherfils-Vicini, Julienb; Cremer, Isabelleb; Debré, Patricea; Vieillard, Vincenta

doi: 10.1097/QAD.0b013e3282f46e7c
Basic Science

Background: γδ T cells share with natural killer (NK) cells many effector capabilities and cell-surface proteins, including the NKG2 receptor family. A subset of γδ T cells that express the variable Vδ1 region plays a critical role in immune regulation, tumour surveillance and viral infection. Dramatic expansion of Vδ1 T cells has been observed in HIV disease.

Objective: To determine if NKG2C expression on Vδ1 T cells during HIV-1 infection is correlated with CD4 cell count and involved in lysis of CD4 T cells.

Methods: γδ T cells from viraemic HIV-infected patients were examined. Expression of NK cell markers was analyzed by flow cytometry. The cytolytic activity of Vδ1 T cells was determined by either 51Cr-release assays or degranulation assays against HLA-E-transfected 721.221 cells or HIV-infected CD4 primary T cells.

Results: The expression of C-type lectin NKG2 receptors was sharply modulated on γδ T cells in patients with HIV infection. A profound decrease of Vδ1 T cells bearing inhibitory NKG2A receptors corresponded to a drastic expansion of a distinct population of Vδ1 T cells expressing a functional activating NKG2C receptor. Engagement of HLA-E, the ligand of both NKG2A and NKG2C, which is specifically induced on HIV-infected CD4 T cells, substantially enhanced the Vδ1 T cell-mediated cytotoxicity.

Conclusions: These results raise the possibility that induction of NKG2C expression on Vδ1 T cells plays a key role in the destruction of HIV-infected CD4 T cells during HIV disease.

From the aInstitut National de la Santé et de la Recherche Scientifique U543, Université Pierre et Marie Curie Paris-6, France

bINSERM U872, Centre de recherche des Cordeliers, Université Pierre et Marie Curie Paris-6 and Université Paris Descartes, Paris, France.

Received 31 May, 2007

Revised 29 October, 2007

Accepted 13 November, 2007

Correspondence to Dr V. Vieillard, INSERM U543, Hôpital Pitié-Salpêtrière, Paris, F-75013, France. E-mail:

© 2008 Lippincott Williams & Wilkins, Inc.